Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

被引：0
|
作者：
Serrano, C. [1 ]
Blay, J-Y. [2 ]
Rutkowski, P. [3 ]
Gelderblom, H. [4 ]
Stacchiotti, S. [5 ]
Falcon Gonzalez, A. [6 ,7 ]
Desai, J. [8 ]
Le Cesne, A. [9 ]
Ferraresi, V. [10 ]
Palmerini, E. [11 ]
Wilky, B. A. [12 ]
Wagner, A. J. [13 ]
Bernthal, N. M. [14 ]
van de Sande, M. [15 ]
Narasimhan, S. [16 ]
Harrow, B. [16 ]
Sharma, M. G. [16 ]
Ruiz-Soto, R. [16 ]
Sherman, M. L. [16 ]
Tap, W. D. [17 ]
机构：
[1] Vall dHebron Inst Oncol, Sarcoma Translat Res, Barcelona, Spain
[2] Ctr Leon Berard, Med, Lyon, France
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[4] Leiden Univ Med Ctr, Med Oncol, Leiden, Netherlands
[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[6] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain
[7] Inst BioMed Sevilla, Seville, Spain
[8] Peter MacCallum Canc Ctr, Clin Res, Melbourne, Vic, Australia
[9] Gustave Roussy, Inst Cancerol, Villejuif, France
[10] IRCCS Ist Nazl Tumori Regina Elena, Sarcomas & Rare Tumors Dept Unit, Rome, Italy
[11] Ist Ortoped Rizzoli, DIMES Expt Diagnost & Specialty Med, Bologna, Italy
[12] Univ Colorado, Ctr Canc, Med Oncol, Aurora, CO USA
[13] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[14] Univ Calif Los Angeles, Orthopaed Surg, Los Angeles, CA USA
[15] Leiden Univ Med Ctr, Orthoped Oncol, Leiden, Netherlands
[16] Deciphera Pharmaceut LLC, Clin Dev, Waltham, MA USA
[17] Mem Sloan Kettering Canc Ctr, Sarcoma Med Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1860
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1769P
引用
收藏
页码：S1053 / S1053
页数：1
相关论文
共 50 条
  • [21] Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma
    Thomas, Sajeve S.
    Chesney, Jason A.
    Hamid, Omid
    In, Gino K.
    Shoushtari, Alexander N.
    Samhouri, Yazan
    Hari, Parameswaran
    Ramsingh, Giridharan
    Prabhakar, Prakash
    Mclaughlin, Lauren
    Warner, Allison Betof
    CANCER RESEARCH, 2024, 84 (07)
  • [22] Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
    Ritchlin, Christopher T.
    Deodhar, Atul
    Boehncke, Wolf-Henning
    Soriano, Enrique R.
    Kollmeier, Alexa P.
    Xu, Xie L.
    Zazzetti, Federico
    Shawi, May
    Jiang, Yusang
    Sheng, Shihong
    Helliwell, Philip S.
    ACR OPEN RHEUMATOLOGY, 2023, 5 (03) : 149 - 164
  • [23] Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.
    LoRusso, P.
    Krop, I. E.
    Burris, H. A., III
    Vukelja, S. J.
    Miller, K.
    Zheng, M.
    Chu, Y.
    Lu, M.
    Amler, L. C.
    Rugo, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Phase III study evaluating efficacy and safety of MK-6482+lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy.
    Motzer, Robert J.
    Liu, Yanfang
    Perini, Rodolfo F.
    Zhang, Yayan
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [25] INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
    Grande, Enrique
    Alonso Gordoa, Teresa
    Reig Torras, Oscar
    Esteban, Emilio
    Castellano, Daniel
    Garcia del Muro, Xavier
    Mendez Vidal, Maria Jose
    Garcia-Donas, Jesus
    Angel Arranz, Jose
    Suarez Rodriguez, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
    Delforge, Michel
    Richter, Joshua
    Cohen, Yael C.
    Corradini, Paolo
    Sborov, Douglas W.
    Lesokhin, Alexander M.
    Berdeja, Jesus G.
    Gatt, Moshe E.
    Paris, Laura
    Dachs, Laura Rosinol
    Quach, Hang
    Kanwar, Manisha
    Catalani, Olivier
    Sewpaul, Paresh
    Wassner-Fritsch, Elisabeth
    Mishra, Ameet
    Trunzer, Kerstin
    Kumar, Shaji
    BLOOD, 2024, 144 : 4733 - 4734
  • [27] A phase II study to evaluate safety and efficacy of PD-1 blockade plus anti-EGFR target therapy plus chemotherapy in patients with advanced penile squamous cell carcinoma
    Shi, Y.
    An, X.
    Yan, R.
    Yao, K.
    Xue, C.
    Guo, S.
    Liu, T.
    Li, J.
    Ma, H.
    Tian, L.
    Zhou, F.
    Shi, Y.
    Han, H.
    EUROPEAN UROLOGY, 2021, 79 : S933 - S933
  • [28] Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy
    Lewis, K. D.
    Fury, M. G.
    Stankevich, E.
    Mathias, M.
    Mohan, K. K.
    Li, S.
    Nunnink, K.
    Perry, C.
    Narwal, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 440 - 440
  • [29] A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non-small-cell lung cancer who have progressed after anti-PD-1/L1 therapy
    Zhao, Yuguang
    Chen, Xiao
    Yao, Jun
    Long, Jianlin
    Mao, Yong
    Wu, Di
    Zang, Aimin
    Zhao, Jun
    Liu, Ziling
    Meng, Rui
    Chen, Ye
    Luo, Yang
    Guo, Qun
    Li, Li
    Cui, Jiuwei
    CANCER MEDICINE, 2024, 13 (03):
  • [30] A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study
    van Akkooi, A. C. J.
    Ascierto, P. A.
    Becker, J. C.
    Nathan, P.
    Nghiem, P.
    Ostermeier, U.
    Reimann, P. G.
    Hermann, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S767 - S768
12345